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Abstract  
The purpose of the study was to identify differential trajectories of patient compliance in a 
clinical trial and to determine demographic and health risk factors associated with compliance 
trajectory membership. The data was obtained from an 18 month, double-blinded, placebo-
controlled trial looking at the long-term impact of increased dietary protein on bone mass in 
older men and women. Two hundred and eight subjects were randomized to either a protein 
treatment or carbohydrate placebo group. Statistical analysis utilized a group-based trajectory 
modeling framework to identify distinct clusters of individuals who follow similar compliance 
trajectories over time. Post hoc analysis using multinomial and standard logistic regression 
models were conducted to incorporate risks factors associated with compliance group 
membership. A four-group trajectory model was selected and determined that reported adverse 
event was a significant risk factor. This analysis will provide supplementation to the standard 
intention-to-treat analysis to understand how efficacy is driven by compliance and will pave the 
way to improve compliance in subsequent protein-supplemented trials.  
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1. Introduction 
 
Osteoporosis, a skeletal disorder characterized by low bone density and micro-architectural 
deterioration of bone tissue, affects over 10 million persons in the United States.1 This 
predisposition increases the risk of osteoporotic fractures, a major cause of morbidity and 
disability in the elderly.2 It is projected that by 2025, the direct costs of inpatient medical 
services and nursing home care will exceed $27 billion in hip fractures alone, not to mention 
indirect costs associated with loss of productivity and a reduction in quality of life due to 
disability.3,4 The World Health Organization (WHO) defines osteoporosis based on a 
measurement of bone mineral density (BMD), where individuals with BMD levels more than 2.5 
standard deviations below the young adult reference mean are considered to have osteoporosis.5  
The dual-energy X-ray absorptiometry (DEXA) is currently regarded as the gold standard to 
measure BMD.5  
 
Nutrition plays an important role in the development and maintenance of bone mass and the 
prevention and treatment of osteoporosis.1,2,5,6 Calcium is one of the main bone-forming minerals 
and contributors in the attainment of peak bone mass, and vitamin D is also required for optimal 
calcium absorption.1,2,6 There is evidence to suggest the importance of dietary protein as a key 
nutrient in the regulation of calcium metabolism and homeostasis.7–11 A systematic review of 18 
cross sectional surveys indicated a significantly positive association between dietary protein and 
lumbar spine BMD, a clinically meaningful outcome (rpooled =0.143, 95% CI: 0.10, 0.20).12 This 
was validated through a meta-analysis of six randomized placebo-controlled trials, indicating a 
positive influence of protein supplementation on lumbar spine BMD.12 However, the long-term 
effects of dietary protein on skeletal health and fracture risk remains uncertain.12 Furthermore, in 
many of these intervention-based trials, compliance with respect to protein supplementation has 
not been thoroughly examined. Since elevated BMD is demonstrated through increased dietary 
protein consumption, BMD is arguably driven by compliance. This suggests a dose-response 
relationship between compliance and BMD; better compliance of dietary protein results in a 
greater increase in BMD. Therefore, monitoring compliance is essential to establishing clinical 
efficacy.13 Identifying the long-term patterns of compliance may pave the way to determine 
thresholds for treatment efficacy.14 
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This provides the motivation for an analysis to (1) identify differential trajectories of patient 
compliance in a long-term randomized clinical trial (RCT) and to (2) determine demographic and 
health risk factors associated with compliance trajectory membership. The analysis will provide 
insight to develop strategies for future RCTs to improve patient compliance in protein-
supplemented trials. The analysis will also provide supplementation to the standard intention-to-
treat (ITT) analysis.15 The principle of ITT requires that all subjects be analyzed based on their 
original randomization scheme regardless of their confounding experience.16 The proposed 
analysis may help to explain the therapeutic mechanisms of the treatment and to address different 
types of questions that are not explained by an ITT analysis.16 For example, if poor compliance 
can be traced to an unpleasant aftertaste of the treatment, this can be easily remedied by 
motivating subjects to focus on the long-term benefits despite the unpleasant aftertaste or even 
improving the taste of the treatment in subsequent studies.16  
 
Statistical methods, such as group-based trajectory modeling (GBTM), have been developed to 
identify distinct clusters of individuals who follow similar trajectories over time.17 GBTM has 
been used in the fields of psychology and sociology, and more recently, it has been seen in 
clinical studies to capture heterogeneity in treatment responses longitudinally.18,19 GBTM draws 
from well developed methodologies including hierarchical and latent class models.20 Several 
studies have looked at patient compliance in a variety of clinical applications using GBTM,14,21–
23  which adds to the motivation in using this methodology for the proposed analysis. 
 
2. Materials and Methods  
 
Study Participants and Procedures  
A data set was obtained from an 18 month, double-blinded, placebo-controlled trial looking at 
the long-term impact of increased dietary protein on bone mass in older men and women.24 Two-
hundred and eight English speaking men and women over the ages of 70 and 60 years were 
selected for the trial, respectively. The subjects were recruited from central and southern-central 
Connecticut, and the study sites were located at Yale University and the University of 
Connecticut’s Health Center (UCHC). Subjects were selected because they naturally consumed a 
moderately low, but adequate protein diet (0.6-1.0 g/kg). After baseline measurements (BMD, 
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heart rate, blood pressure, and height and weight) and screening and safety biochemistries from 
blood and urine samples were taken at the initial visit, eligible subjects were invited back for 
randomization proceedings. Subjects were randomized to either a protein treatment or 
carbohydrate placebo group. Both supplements were formulated to be identical in appearance, 
taste, texture, and caloric content. It was expected that subjects consume 40 g of the protein or 
carbohydrate powder daily by mixing it into their food or drink. Registered dietitians provided 
nutritional counseling during the initial and follow-up visits to (1) stabilize the subjects’ calcium 
and vitamin D intake and to cease all other nutritional supplements that may affect bone 
homeostasis, (2) incorporate the powder supplements into their diets and provide weight 
management, and (3) monitor compliance of treatment. After randomization, subjects were 
followed up after 1.5, 3, 6, 9, 12, 15, and 18 months. It should be noted that at the time the data 
was received, the study was still active. Therefore, the analysis was performed blinded and did 
not take into account treatment groups.  
 
Measures  
For the purposes of this analysis, the outcome variable was percent compliance. The following 
covariates were considered as potential predictors of compliance trajectory membership: baseline 
DEXA lumbar vertebrae 2-4 (L2-4) BMD, BMD T-score, age, gender, study site, reported 
adverse event, physical function measured by the Estimated Populations for Epidemiologic 
Studies of Elderly (EPESE) battery, and self-reported history of depression and/or anxiety.  
(1) Percent Compliance 
After randomization, patients were dispensed a batch of the supplement either containing 
the protein or carbohydrate powder. It was expected that subjects consume 40 g of the 
powder daily, and so the appropriate amount was dispensed and recorded accordingly. 
Subjects were asked to bring any unconsumed powder with them during follow-up visits 
to be weighed. The amount consumed was calculated as the amount dispensed during the 
previous visit minus the unconsumed amount during the follow-up visit. The expected 
amount consumed was calculated as 40 g of powder multiplied by the days between each 
visit. Therefore percent compliance was calculated as: 
 
Percent Compliance = (Amount Consumed / Expected Amount) x 100 
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Compliance data was available after the second visit, and repeated measurements were 
taken during visits 3, 4, 5, 6, 7, 8, and 9 (i.e. during months 1.5, 3, 6, 9, 12, 15, and 18). 
Occasionally, there were subjects who consumed more than 40 g of powder daily, on 
average. Since these subjects exceed the expected amount and therefore were fully 
compliant, they were considered as having one-hundred percent compliance. Conversely, 
missing data from subjects that had dropped out of the study or stopped treatment but 
remained in the study for follow-ups were considered to be fully non-compliant. These 
subjects were recorded as having zero percent compliance.  
(2) DEXA L2-4 BMD and T-score  
The DEXA L2-4 BMD (g/ cm2) was the primary endpoint of the clinical trial. 
Measurements were taken initially during the screening visit and remeasured after 9 and 
18 months (visits 6 and 9). Baseline BMD was only considered for this analysis to 
evaluate the initial disease severity. In addition, the T-score, a clinically relevant tool for 
diagnosing osteoporosis, was also considered. A T-score is defined as the number of 
standard deviations from the mean BMD in relation to a young healthy adult population.5 
Since subjects were considered to have osteoporosis if their T-score was less than -2.5, 
this variable was categorized to ≤ -2.5 as having clinically diagnosed osteoporosis and    
> -2.5 as having moderately low (osteopenia) to normal BMD levels.  
(3) Demographic and Other Health Measurements  
Since women are at greater risk of developing osteoporosis,25 the trial over-sampled 
women to men that were 60 and 70 years of age or older, respectively. The study sites 
were located either at Yale University or UCHC. Adverse events were recorded at 
baseline and follow-up visits. An adverse event is defined as any injurious falls to the 
ground that resulted in bruises, strains, cuts and abrasion, back pain, and/or fractures.24 A 
record of any adverse event and its severity was kept throughout the trial. The baseline 
reported adverse event was only used in the analysis. Self-reported history of depression 
and/or anxiety was also considered as relevant predictor. Finally, physical performance 
among older populations was measured by the EPESE battery, which consisted of three 
domains of lower extremity function to assess gait speed, standing balance, and time to 
rise from a chair five times.26–28 Within each domain, a score of 0 denoted an inability to 
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complete the test, while a score of 4 represented the highest level of performance; the 
maximum total EPESE score was 12.28 
 
3.  Statistical Analysis 
 
Statistical analysis encompassed (1) descriptive statistics of the study characteristics, (2) model 
selection for determining the compliance trajectory groups using GBTM, and (3) statistical 
inference for determining predictors associated with compliance trajectory membership using 
multinomial and standard logistic regression models. All data analysis was carried out using SAS 
version 9.2 and PROC TRAJ, a SAS macro for GBTM developed by Bobby L. Jones.19 
 
Group-Based Trajectory Modeling  
Group-based trajectory modeling (GBTM), also referred to as latent class growth modeling, is a 
statistical tool used to identify distinct clusters of individuals, called trajectory groups, who 
follow a similar developmental trajectory on an outcome of interest.17,19 Trajectory groups can be 
thought of as unobserved (latent) longitudinal strata where population variability is captured by 
the differential trajectories across groups.17,29 GBTM uses a semi-parametric group-based 
approach that draws from two well-developed methodologies – hierarchical modeling and latent 
curve analysis.20 The key difference among these models is that hierarchical and latent class 
models utilizes multivariate continuous distributions to explain the population-level variability in 
growth, while GBTM uses a multinomial-based strategy to identify relatively homogeneous 
clusters of developmental trajectories.20 GBTM is a special case of growth mixture models 
(GMM) in that it assumes no random effects in each of the group’s trajectories; GMM relaxes 
this assumption and allows for variation within each of the trajectory groups.17,30 GBTM has 
been widely used in the fields of developmental and abnormal psychology as well as modeling 
behavior in sociological and criminological studies.19 More recently, GBTM has been applied to 
clinical research to map the developmental course of symptoms and to assess heterogeneity in 
response to clinical interventions.17 
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 Derivation of the Group-Based Trajectory Model19,31,32 
Let 𝑌𝑖 = {𝑦𝑖1,𝑦𝑖2,𝑦𝑖3 …𝑦𝑖𝑇} denote the repeated measurements of individual i over T 
measurements. Since measurements are reassessed at each visit t (i.e. 1st, 2nd, 3rd visit, etc.), it is 
expected that the number of visits be the same across individuals. GBTM assumes that 
individuals fall within a particular group J such that 
𝑃(𝑌𝑖) =  �𝜋𝑗𝑃(𝑌𝑖|𝐽 = 𝑗) = �𝜋𝑗𝑃𝑗(𝑌𝑖)𝐽
𝑗=1
𝐽
𝑗=1
 
where 𝜋𝑗 is the probability of membership in group j, and 𝑃𝑗(𝑌𝑖) is the conditional probability of 
𝑌𝑖 given membership in group j. The model makes a strong assumption that measurements for 
individual i are independent of each other, conditional on membership in group j. Therefore, 
𝑃𝑗(𝑌𝑖) =  ∏ 𝑝𝑗𝑡(𝑦𝑖𝑡)𝑇𝑡=1 . 𝜋𝑗 is estimated using a multinomial logit function to ensure that the 
probabilities fall between 0 and 1: 
𝜋𝑗 = 𝑒𝜃𝑗
∑ 𝑒𝜃𝑗𝐽𝑗=1
 
where 𝜃1 is initialized at 0. GBTM is able to handle continuous (censored normal), count (zero-
inflated Poisson), and binary outcome data by selecting a form of 𝑝𝑗𝑡(𝑦𝑖𝑡) to fit the appropriate 
data type. For continuous data, GBTM uses a polynomial relationship between the outcome and 
time variable: 
𝑦𝑖𝑡
∗𝑗 = 𝛽0𝑗 + 𝛽1𝑗𝑇𝑖𝑚𝑒𝑖𝑡 + 𝛽2𝑗𝑇𝑖𝑚𝑒𝑖𝑡2 + 𝛽3𝑗𝑇𝑖𝑚𝑒𝑖𝑡3 + 𝛽4𝑗𝑇𝑖𝑚𝑒𝑖𝑡4 + 𝜀𝑖𝑡 
 
where 𝑦𝑖𝑡
∗𝑗is a latent variable and link between the outcome and time variable, and 𝜀𝑖𝑡 is a random 
error term that follows a normal distribution with mean of zero and constant variance 𝜎2. Many 
statistical packages that performs GBTM allows specification of the order trajectories up to the 
fourth degree polynomial.19,30,31  
 
Model Selection of Compliance Trajectories using PROC TRAJ 
GBTM can be applied to a variety of statistical packages including SAS and Mplus.19,30,31 For the 
purposes of this analysis, PROC TRAJ, a SAS macro developed by Bobby L. Jones19 was used 
to perform GBTM to estimate the compliance trajectories. PROC TRAJ assigns group 
membership to each individual where the posterior probability of membership to that group is the 
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highest.19 Parameter estimates are based on maximum likelihood via the quasi-Newton 
optimization procedure, and standard errors are approximated by a fist-order Taylor series 
expansion.23 PROC TRAJ allows specification of the trajectories up to the fourth degree 
polynomial.19,31 It includes subjects with missing longitudinal data and time-varying covariates; 
however missing time-stable covariates are excluded from the analysis.19 Covariates can be 
incorporated into the model either by adding them simultaneously in the PROC TRAJ statement, 
or by performing post-hoc analysis using a multinomial logistic regression model. In this 
analysis, both methods were performed to compare the consistency of the results.  
 
Model selection involved a two-step process to determine the best model for each trajectory 
group (i.e. best model containing 1-, 2-, 3-group trajectories, etc.) and the best overall model 
with PROC TRAJ. The strategy outlined by Andruff et al.32 to determine the best model for each 
trajectory group utilized a combination of visual inspection of the fitted compliance trajectories 
overlaid with the mean trajectories at each time point, and tests of significance on whether or not 
the time parameter estimates differed from zero. The significance level α was set at 0.05. For 
each trajectory group, a third order polynomial model was fitted. A new model was refitted of 
increased or decreased order depending on the significance of the third order parameter 
estimates. This process was repeated until the highest order term achieved significance, and the 
fitted model appeared adequate from the trajectory plot. Once a best model was chosen for each 
trajectory group, the best overall model was selected using the Bayesian Information Criteria 
(BIC) and the log Bayes factor to compare models. The log Bayes factor is approximated as: 
 log  𝐵𝑎𝑦𝑒𝑠 𝑓𝑎𝑐𝑡𝑜𝑟 = 2𝑙𝑜𝑔𝑒(𝐵10) ≈ 2(∆𝐵𝐼𝐶) 
 
where ∆𝐵𝐼𝐶 is the difference between the BIC of the larger model (alternative) model and the 
BIC of the smaller (null) model.19 The log Bayes factor is interpreted as the degree of evidence 
favoring the larger model and is shown in the table below.  
 
Interpretation of the Log Bayes Factor 
Log Bayes Factor Evidence against H0 
0 to 2 Weak 
2 to 6 Positive 
6 to 10 Strong 
> 10 Very Strong 
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To ensure that PROC TRAJ accurately assigned each individual to the appropriate trajectory 
group, Nagin outlined four criteria to assess model adequacy: (1) the estimated probability of 
group membership (𝜋�𝑗) should correspond closely to the proportion classified in that group based 
on the highest posterior probability, (2) the confidence intervals around 𝜋�𝑗 should be reasonably 
tight, (3) the average posterior probability (AvePP) of group membership for individuals 
assigned to each group should exceed the 0.7 threshold, and (4) the odds of correct classification 
(OCC) should exceed the minimum threshold of 5.17,18 For each group j, the OCC is calculated 
as: 
𝑂𝐶𝐶𝑗 = 𝐴𝑣𝑒𝑃𝑃/(1 − 𝐴𝑣𝑒𝑃𝑃)𝜋�𝑗/(1 − 𝜋�𝑗)  
 
Simultaneous and Post-hoc Analysis using Multinomial and Standard Logistic Regression 
GBTM allows the group membership probabilities to vary as a function of time-stable 
characteristics for an individual, and therefore covariates can be added simultaneously in the 
PROC TRAJ statement to predict trajectory group membership.31 Measured covariates were 
included in the model simultaneously to determine the impact of a given risk factor on the 
probability of group membership in a specified trajectory group compared to a reference group.31 
Given that the trajectory groups followed a multinomial distribution, post-hoc analysis using 
multinomial logistic regression was also conducted to determine whether the measured 
covariates were significant predictors of compliance trajectory group membership. The results of 
the simultaneous and post-hoc analysis were compared for consistency. Furthermore, the groups 
in the multinomial analysis were collapsed into a binary outcome variable indicating compliant 
or non-compliant subjects. A standard logistic regression model was then performed to take into 
account potential predictors for compliance. The Hosmer and Lemeshow Chi-square test for 
goodness of fit was used to assess model adequacy, and the R2 and max-rescaled R2 was also 
reported. Since R2 only achieves a maximum value of less than 1 when discrete variables are 
included in a logistic regression model, the max-rescaled R2 provides a more accurate assessment 
of model fit.33 
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3. Results   
 
Description of the Sample 
Two-hundred and eight subjects were considered for the analysis to identify differential 
trajectories of patient compliance and to determine risk factors associated with compliance group 
membership. A description of the study participants can be found in Table 1. The mean age of 
the subjects was 69.8 ± 6.2 years. As females are at higher risk of developing osteoporosis, they 
were over-sampled and comprised of 85.6% of the study subjects. The majority of the subjects 
(92.2%) had a T-score greater than -2.5, indicating that they did not have clinically diagnosed 
osteoporosis at the beginning of the study. The mean EPESE score was 11.3 ± 1.1. Eighty-two 
subjects reported an adverse event at baseline, while only 23 reported any history of depression 
and/or anxiety.  
 
Model Selection for Determining Compliance Trajectory Groups 
Model selection for GBTM was assessed by comparing the BIC, log Bayes factor, and estimated 
group proportions for five trajectory models (i.e. 1-, 2-, 3-, 4-, and 5-group models) (Table 2). A 
6-group model failed to achieve convergence and was not included in the model selection. The 
second group of the 5-group model contained only 2.14% of the total sample; therefore, the 
sample size was not large enough to perform further analysis with multinomial logistic 
regression. As a result, the 4-group model was chosen as the best model as it identified four 
distinct trajectories with estimated group proportions well over the 5% threshold (Group 1: 
23.5%, Group 2: 36.9%, Group 3: 19.8%, and Group 4: 19.8%). 
 
A plot of the individual trajectories of percent compliance at each visit (Figure 1) indicated a 
large degree of heterogeneity among the subject-specific percent compliance. After performing 
GBTM, the fitted model was able to identify four distinct trajectory groups (Figure 2). Group 1 
(red) was identified as “severely noncompliant.” Percent compliance within group 3 (blue) 
decreased over time and these subjects were termed “delayed noncompliant.” Groups 2 (green) 
and 4 (black) showed consistently moderate to high levels of compliance and were identified as 
“moderately compliant” and near-perfect compliant” subjects, respectively. For comparison, a 
panel of the 1-, 2-, 3-, and 5-group fitted models can be found in Figure 3.  
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The parameter estimates of the differential trajectories over time from the 4-group model are 
shown in Table 3. The estimates of the highest degree polynomial within each group were found 
be to significant (p < 0.001). To ensure that GBTM accurately assigned each individual to the 
appropriate trajectory group, diagnostics were performed to check for model adequacy in Table 
4. The estimated probabilities of group membership and the proportion classified to that group 
showed close correspondence with each other. The width of the 95% confidence intervals of the 
estimated probabilities appeared reasonably narrow, and the AvePP and OCC significantly met 
the minimum thresholds of 0.7 and 5, respectively. Therefore, the diagnostics suggest that 
GBTM was successful in accurately assigning each individual to the appropriate trajectory 
group.  
 
Predictors of Compliance Group Membership 
Bivariate analysis of the study characteristics across the four trajectory groups is shown in Table 
5. There were no significant associations between the compliance trajectory groups and the study 
characteristics. Although not significant (p = 0.268), there were a greater proportion of subjects 
with clinically diagnosed osteoporosis (T-score ≤ -2.5) among the severely (14.6 %) and delayed 
(7.7%) noncompliant groups compared to the moderately (5.3%) and near-perfect compliant 
groups (4.8%). The continuous DEXA measurement for BMD showed a consistent and slightly 
more significant association (p = 0.092). Over half of the subjects within the delayed 
noncompliant group (53.7%) reported an adverse event at baseline in comparison to the severely 
noncompliant (32.7%), moderately compliant (36.8%), and near-perfect compliant (38.1) 
subjects (p-value = 0.198).  
 
PROC TRAJ has the capabilities to simultaneously identify differential trajectory groups and 
take into account potential risk factors; however, when this was applied, convergence was not 
achieved past two trajectory groups. Therefore, the results of the post hoc analysis were only 
shown. One-hundred and sixty eight subjects with complete data were included in multinomial 
logistic regression. Given that the T-score calculation was based off of the DEXA BMD and 
therefore were highly correlated with each other, two separate models were performed. Table 6 
shows the multivariate regression model that includes the BMD T-score (model 1), while Table 7 
shows the model containing DEXA BMD (model 2). 
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The near-perfect compliant group was set as the reference group. None of the predictors 
measured were found to be significant for model 1. When controlling for all other variables, 
subjects who were severely noncompliant were 3.36 times more likely to have clinically 
diagnosed osteoporosis (T-score ≤ -2.5) compared to those with near-perfect compliance (p = 
0.176, 95% CI: 0.58, 19.34). Subjects with delayed noncompliance were more likely to report an 
adverse event compared to subjects with near-perfect compliance (AOR = 2.27, 95% CI: 0.81, 
6.34). On the other hand, DEXA BMD was found to be significant in model 2 (p = 0.036). The 
severely (AOR = 0.26, 95% CI: 0.02, 3.89) and delayed (AOR = 0.64, 95% CI: 0.04, 11.02) 
noncompliant groups were associated with lower BMD levels, while the moderately compliant 
group (AOR = 6.66, 95% CI: 0.67, 65.8) showed increased BMD levels compared to the near-
perfect compliant group. However, none of these estimates were significant, and the wide 95% 
confidence intervals suggest that the reliability of the estimates is questionable. The significance 
of the Wald Chi-square test implies significant associations for DEXA BMD comparing a 
different reference group.  
 
Since the severely and delayed noncompliant groups were presumably represented by 
noncompliant subjects, and the moderately and near-perfect compliant groups as the compliant 
subjects, the four groups were collapsed into a binary outcome. The probability of 
noncompliance (i.e. comparison of noncompliant versus compliant group) was modeled using 
standard logistic regression for models 1 and 2 (Tables 8 and 9). For both models, reported 
adverse event was significantly associated with noncompliance (model 1: p = 0.033, model 2:  
p = 0.35). Noncompliant subjects were 51% less likely to have reported an adverse event 
compared to compliant subjects (model 1: AOR = 0.49, 95% CI: 0.25, 0.94, model 2: AOR = 
0.49, 95% CI: 0.26, 0.95). However, the max-rescaled R2 of both multinomial (model 1: max-
rescaled R2 = 0.164, model 2: max-rescaled R2 = 0.173) and standard logistic regression (model 
1: max-rescaled R2 = 0.075, model 2: max-rescaled R2 = 0.082) models did not indicate an 
adequate fit of the data, suggesting that other important risk factors were overlooked in 
explaining the variability of the compliance trajectory groups.  
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4. Discussion  
 
GBTM was able to accurately identify four distinct compliance trajectory groups – severely 
noncompliant, delayed noncompliant, moderately compliant, and near-perfect compliant groups. 
However, because the parameter estimates for the risk factors did not achieve convergence when 
added simultaneously to PROC TRAJ, the results of the simultaneous and post hoc analysis were 
not compared. Jones argues that the post-hoc analysis does not account for the uncertainty in 
group assignment and this could lead to bias; incorporating the predictors simultaneously 
accounts for this automatically.19 Nonetheless, the procedure was shown to accurately identify 
four distinct trajectory groups that follow a multinomial distribution based on the model 
diagnostics for GBTM, and so the post hoc analysis was justified.   
 
While there were no significant predictors of compliance group membership within the first 
multinomial logistic model, DEXA BMD was found to be a significant predictor within the 
second model. The wide variability around the 95% confidence intervals as well as the limited 
number of subjects diagnosed with osteoporosis, on the other hand, suggest that the estimates 
may not be reliable. As a result of the inclusion/exclusion criteria, relatively healthy subjects 
were selected for the trial. This was evident as subjects had a mean EPESE score of 11.3, and 
these scores were found not to be statistically different across the four compliance groups (p = 
0.719). The main inclusion criterion was that they naturally consumed a moderately low, but 
adequate protein diet. The trial excluded subjects with a BMD T-score of < -2.5 with the 
exception of subjects who declined treatment for anti-osteoporotic medications throughout the 
trial. Thus, only 16 out of 208 subjects were found to have clinically diagnosed osteoporosis. 
This greatly limits the statistical power to conduct a multinomial logistic regression analysis and 
to compare the four compliance groups. GBTM is preferable  when the sample size is greater 
than 300,18 and so this adds to a limitation in the analysis.   
 
The nature of the clinical trial also limited the analysis in terms of potential risk factors that 
could have been analyzed to predict compliance group membership. The trial restricted subjects 
to those with normal BMI levels (i.e. excluded BMI levels < 19 and > 32). An investigation of 
whether or not subjects with low BMI were more likely to comply with the treatment protocol 
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compared to those with normal to high levels would have provided much insight. Data on 
reported history of gastrointestinal disorders (i.e. Crohn’s disease, colitis, ulcers) was also 
available to determine whether the supplements had an adverse effect on these individuals, 
making them less likely to be compliant. Unfortunately, there were not enough subjects that 
responded to these questions, and so this was not considered in the analysis. Socioeconomic 
status (SES), measured by education level, might also have been an important predictor as there 
is a direct correlation between education and health.34 Subjects with higher education levels are 
more likely to be health conscious, and so they might be motivated to take the supplements 
regularly if they knew it would be beneficial to their health. However, subjects within the clinical 
trial comprised of mainly retired and working class individuals, and so SES data was not 
available.  
 
A major limitation to this analysis was that the clinical trial was still active at the time the data 
was received. As a result, the analysis did not take into account the treatment effect as a predictor 
because the study had been blinded to the treatment allocation. Data on the treatment group 
would have provided insight to uncover potential discrepancies in compliance between the 
protein and carbohydrate groups. If it was shown that subjects who received the protein 
treatment were more likely to fall within the noncompliant groups (i.e. severely and delayed 
noncompliance) compared to the compliant groups (i.e. moderate and near-perfect compliance), 
this may help to explain why the treatment was not efficacious to increase BMD levels. It is 
possible that efficacy for the treatment effect was undermined by compliance. Equally, if 
subjects who received the protein treatment were more likely to be compliant compared to the 
carbohydrate-supplemented group, then the magnitude for the association between BMD levels 
and the treatment effect might have been overestimated. Therefore, understanding the 
mechanisms behind compliance is essential to establishing clinical efficacy.  
 
While there were no significant predictors of compliance group membership in the multinomial 
logistic models, reported adverse events was found to be a significant predictor in the standard 
logistic regression models. Subjects who had reported an adverse event throughout the trial were 
more likely to be compliant with their treatment. This makes intuitive sense because subjects 
who believe that they are more susceptible to having lower BMD because of an adverse event 
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will more likely comply with the medication in hopes of increasing their BMD levels. This idea 
is known as the Becker’s health belief model. It postulates that the likelihood that patients follow 
a health regimen is related to their motivation and incentive to do so.35 The motivation and 
incentive, in this case, is alleviating their adverse event, and so subjects are more likely to 
comply with the protein or carbohydrate supplements. 
 
In summary, the analysis using the GBTM methodology will provide supplementation to the 
clinical trial to explain how efficacy is driven by compliance. By identifying the differential 
effects in reporting an adverse event at baseline and its impact on compliance, subgroup analysis 
can be performed to compare BMD levels over time between subjects who did and did not 
reported an adverse event at baseline. If it is shown that subjects who reported an adverse event 
had a greater treatment difference of increased BMD compared to those who did not report an 
adverse event, then future studies can be develop to target subjects with adverse events. But 
because of the low sample size and the risk of type I error, subgroup analysis should be 
approached with caution; these analysis are merely speculative and must be followed up with 
confirmatory studies16 Nevertheless, exploring trajectory groups using GBTM is advantageous in 
identifying more direct thresholds of compliance for establishing clinical efficacy.  
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Table 1. Description of the Samplea 
 
Characteristic  N = 208b 
Age (years) 69.8 ± 6.2 
Gender  
   Male 30 (14.4) 
   Female 178 (85.6) 
Study Site  
   Yale 66 (31.7) 
   UCHC 142 (68.3) 
DEXA L2-4 BMD (g/cm2) 1.2 ± 0.2 
T-score  
   ≤ -2.5 16 (7.8) 
   > -2.5 188 (92.2) 
Adverse Event  
   Yes 82 (39.4) 
   No 126 (60.6) 
EPESE Score 11.3 ± 1.1 
History of Depression/ Anxiety  
   Yes 23 (13.3) 
   No 150 (86.7) 
a Table values are mean ± SD for continuous variables and n (%) for categorical variables  
b Numbers may not sum to total due to missing data, and percentages may not sum to 100% due to rounding 
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Table 2. Model Selection using BIC, Log Bayes Factor, and Estimated Group Proportions Using 
GBTM in Determining Compliance Trajectory Groups 
 
    Estimated Group Proportions 
Number of 
Groups 
BIC Log Bayes 
Factor 
Group 1 Group 2 Group 3 Group 4 Group 5 
1 -4328.50  100.00     
2 -3755.63 1145.74 41.98 58.02    
3 -3722.41 66.44 40.93 16.09 42.98   
4 -3602.30 240.22 23.50 36.87 19.81 19.82  
5 -3589.89 24.82 23.62 2.14 19.29 41.05 13.90 
 
 
 
Table 3. Final Model Containing the 4-Group Compliance Trajectories 
 
Group Parameter Estimatea 
(95% CI) 
t-statistic P-value 
Severely Noncompliant    
   Intercept 170.19 (112.87 , 227.51) 5.82 < 0.001 
   Linear -52.60 (-70.43 , -34.77) -5.78 < 0.001 
Delayed Noncompliant    
   Intercept 33.84 (-38.66 , 106.34) 0.92 0.361 
   Linear 31.96 (-0.13 , 64.05) 1.95 0.051 
   Quadratic -6.15 (-9.48 , -2.82) -3.62 < 0.001 
Moderately Compliant    
   Intercept 76.75 (71.35 , 82.15) 27.88 < 0.001 
Near-Perfect Compliant    
   Intercept 114.98 (103.31 , 126.65) 31.47 < 0.001 
a Parameter estimates denote the differential time polynomial 
 
 
 
Table 4. Model Diagnostics for GBTM 
     
Group Group Membership Model 
Estimates (95% CI) 
Proportion 
Classified in Group 
Average Posterior 
Probabilitya 
Odds of Correct 
Classificationb 
Severely Noncompliant 0.24 (0.17 , 0.30) 0.24 0.979 156 
Delayed Noncompliant 0.20 (0.14 , 0.26) 0.20 0.964 107 
Moderately Compliant 0.37 (0.26 , 0.48) 0.37 0.917 19 
Near-Perfect Compliant 0.20 (0.09 , 0.30) 0.20 0.858 24 
a  Average posterior probability for each group should exceed the minimum threshold of 0.7 
b  Minimum odds of correct classification should exceed 5  
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Table 5. Description of the Sample by Compliance Trajectory Group 
      
 Compliance Trajectory Groupsab  
Characteristic Severely 
Noncompliant 
(n = 49) 
Delayed 
Noncompliant 
(n = 41) 
Moderately 
Compliant 
(n = 76) 
Near-Perfect 
Compliant 
(n = 42) 
P-valuec 
Age 70.3 ± 6.7 69.0 ± 6.3 69.6 ± 6.4 70.6 ± 5.1 0.639 
Gender     0.079 
   Male 7 (14.3) 3 (7.3) 9 (11.8) 11 (26.2)  
   Female 42 (85.7) 38 (92.7) 67 (88.2) 31 (73.8)  
Study Site     0.944 
   Yale 15 (30.6) 14 (34.2) 25 (32.9) 12 (28.6)  
   UCHC 34 (69.4) 27 (65.9) 51 (67.1) 30 (71.4)  
DEXA L2-4 BMD 
(g/cm2) 
1.1 ± 0.2 1.1 ± 0.2 1.2 ± 0.3 1.2 ± 0.2 0.092 
T-score     0.268 
   ≤ -2.5 7(14.6) 3 (7.7) 4 (5.3) 2 (4.8)  
   > -2.5 41 (85.4) 36 (92.3) 71 (94.7) 40 (95.2)  
Adverse Event     0.198 
   Yes 16 (32.7) 22 (53.7) 28 (36.8) 16 (38.1)  
   No 33 (67.4) 19 (46.3) 48 (63.2) 26 (61.9)  
EPESE Score 11.3 ± 1.2 11.2 ± 1.4 11.4 ± 0.9 11.3 ± 1.1 0.719 
History of 
Depression/ Anxiety 
    0.283 
   Yes 5 (12.2) 8 (23.5) 6 (9.4) 4 (11.8)  
   No 36 (87.8) 26 (76.5) 58 (90.6) 30 (88.2)  
a  Table values are mean ± SD for continuous variables and  n (%) for categorical variables  
b Numbers may not sum to total due to missing data, and percentages may not sum to 100% due to rounding 
c  P-values are calculated using the Pearson Chi-Square or Fisher’s Exact test for categorical variables and One-Way 
ANOVA for continuous variables 
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Table 6. Multinomial Logistic Regression Model 1: Predictors of Compliance Group Membership (N = 168)ab 
         
 Severely Noncompliant Delayed Noncompliant Moderately Compliant   
Variable AOR 95% CI AOR 95% CI AOR 95% CI Wald χ32 P-value 
Age 1.04 (0.95 , 1.13) 1.00  (0.91 , 1.09) 1.04  (0.96 , 1.12) 1.57 0.666 
Gender 0.31 (0.08 , 1.27) 0.28 (0.06 , 1.37) 0.35 (0.10 , 1.16) 4.40 0.222 
Study Site 0.86 (0.23 , 3.30) 1.62 (0.44 , 6.01) 1.98 (0.64 , 6.19) 2.74 0.433 
Osteoporosis (T-score) 3.36 (0.58 , 19.34) 0.81 (0.09 , 7.06) 0.40 (0.05 , 3.18) 6.96 0.073 
Adverse Event 0.76 (0.28 , 2.08) 2.27 (0.81 , 6.34) 0.71 (0.29 , 1.76) 6.88 0.076 
EPESE Score 0.95 (0.60 , 1.51) 0.85 (0.53 , 1.36) 1.14 (0.73 , 1.79) 1.89 0.596 
History of Depression/     
Anxiety 
1.12 (0.27 , 4.71) 2.34 (0.60 , 9.07) 0.71 (0.17 , 2.90) 3.79 0.285 
a Near-perfect compliant group was set as the reference group  
b R2 = 0.153; max-rescaled R2 =0.164 
 
 
 
Table 7. Multinomial Logistic Regression Model 2: Predictors of Compliance Group Membership (N = 168)ab 
         
 Severely Noncompliant Delayed Noncompliant Moderately Compliant   
Variable AOR 95% CI AOR 95% CI AOR 95% CI Wald χ32 P-value 
Age 1.04 (0.95 , 1.14) 1.00 (0.91 , 1.10) 1.02 (0.94 , 1.11) 1.22 0.748 
Gender 0.36 (0.08 , 1.53) 0.31 (0.06 , 1.55) 0.26 (0.07 , 0.94) 4.76 0.190 
Study Site 0.97 (0.26 , 3.62) 1.44 (0.38 , 5.47) 2.35 (0.73 , 7.57) 3.45 0.328 
DEXA L2-4 BMD (g/cm2) 0.26 (0.02 , 3.89) 0.64 (0.04 , 11.02) 6.66 (0.67 , 65.8) 8.56 0.036 
Adverse Event 0.69 (0.26 , 1.87) 2.27 (0.81 , 6.35) 0.77 (0.31 , 1.91) 6.94 0.074 
EPESE Score 0.94 (0.60 , 1.47) 0.85 (0.53 , 1.36) 1.18 (0.74 , 1.86) 2.24 0.524 
History of Depression/     
Anxiety 
1.13 (0.27 , 4.73) 2.30 (0.59 , 8.94) 0.71 (0.17 , 2.90) 3.70 0.296 
a Near-perfect compliant group was set as the reference group 
b R2 = 0.162; max-rescaled R2 = 0.173 
 
25 
 
Table 8. Logistic Regression Model 1 (N = 168)abc 
   
Variable AOR (95% Confidence Interval) P-value 
Age 1.04 (0.98 , 1.10) 0.224 
Gender 0.55 (0.21 , 1.44) 0.222 
Study Site 1.19 (0.53 , 2.68) 0.680 
Osteoporosis (T-score) 1.39 (0.38 , 5.03) 0.617 
Adverse Event 0.49 (0.25 , 0.94) 0.033 
EPESE Score 1.15 (0.84 , 1.57) 0.388 
History of Depression/ Anxiety 0.53 (0.21 , 1.33) 0.172 
a Adjusted odds ratios compared noncompliant to compliant group 
b R2 = 0.055; max-rescaled R2 =0.075 
c Hosmer and Lemeshow Goodness of Fit χ8
2 = 4.868, p-value = 0.772 
 
 
 
Table 9. Logistic Regression Model 2 (N = 168)abc 
   
Variable AOR (95% Confidence Interval) P-value 
Age 1.03 (0.97 , 1.09) 0.344 
Gender 0.46 (0.17 , 1.27) 0.134 
Study Site 1.42 (0.62 , 3.25) 0.407 
DEXA L2-4 BMD (g/cm2) 2.54 (0.46 , 13.94) 0.283 
Adverse Event 0.49 (0.26 , 0.95) 0.035 
EPESE Score 1.14 (0.84 , 1.56) 0.403 
History of Depression/ Anxiety 0.54 (0.21 , 1.35) 0.185 
a Adjusted odds ratios compared noncompliant to compliant group 
b R2 = 0.060; max-rescaled R2 = 0.082 
c Hosmer and Lemeshow Goodness of Fit χ8
2 = 4.484, p-value = 0.811
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Figure 1. Individual Trajectories of Percent Compliance by Visita 
 
a Individual trajectories were plotted over the seven time points (visits) overlaid by a spline function    
 
Figure 2. Four-Group Compliance Trajectories using GBTMa
a Dashed lines denote the fitted model using GBTM and the solid lines denote the mean percent compliance at each  
time point  
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Figure 3. One-, Two-, Three-, and Five-Group Compliance Trajectories using GBTMa 
 
 
a Dashed lines denote the fitted model using GBTM and the solid lines denote the mean percent compliance at each time point
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